{"filing":{"accession_number":"0001171843-26-006162","cik":"0001738021","ticker":"CMPX","company_name":"Compass Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-22","primary_document":"f8k_092226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326006162/f8k_092226.htm"},"events":[{"id":34208,"run_id":31476,"accession_number":"0001171843-26-006162","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The filing discloses FDA regulatory feedback recommending that Compass conduct a survival-benefit trial before submitting a BLA for tovecimig in biliary tract cancer. This is a material operational/regulatory development affecting the company's clinical development pathway and timeline for a key product candidate. While the company disputes the FDA's recommendation and intends to further engage with the agency, the feedback materially impacts the regulatory strategy and timeline for BLA submission, making it significant to investors assessing the company's ability to advance its lead program.","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37881,"accession_number":"0001171843-26-006162","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses FDA regulatory feedback recommending that Compass conduct a survival-benefit trial before submitting a BLA for tovecimig in biliary tract cancer. This is a material operational/regulatory development affecting the company's clinical development pathway and timeline for a key product candidate. While the company disputes the FDA's recommendation and intends to further engage with the agency, the feedback materially impacts the regulatory strategy and timeline for BLA submission, making it significant to investors assessing the company's ability to advance its lead program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:31:45.309956+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37881,"accession_number":"0001171843-26-006162","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses FDA regulatory feedback recommending that Compass conduct a survival-benefit trial before submitting a BLA for tovecimig in biliary tract cancer. This is a material operational/regulatory development affecting the company's clinical development pathway and timeline for a key product candidate. While the company disputes the FDA's recommendation and intends to further engage with the agency, the feedback materially impacts the regulatory strategy and timeline for BLA submission, making it significant to investors assessing the company's ability to advance its lead program.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T12:31:45.309956+00:00","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-09-22"}]}